Low-dose anti-thymocyte globulin combined with low-dose post-transplant cyclophosphamide: a novel approach to prevent graft-versus-host disease in haploidentical stem cell transplantation.

Ther Adv Hematol · 2025 · PMC12246534 · PMID 40656662

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Similarly, DFS was longer in the low-dose ATG/PTCy group, with a median of 26 months (range: 1.5–118 months), compared to 12 months (range: 0.5–84 months) in the PTCy group; however, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.